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Abstract
Background: The human IGF2-P4 and H19 promoters are highly active in a variety of human cancers (including
bladder cancer), while existing at a nearly undetectable level in the surrounding normal tissue.
Single promoter vectors expressing diphtheria toxin A-fragment (DTA) under the control regulation of IGF2-P4 or
H19 regulatory sequences (IGF2-P4-DTA and H19-DTA) were previously successfully used in cell lines, animal mod-
els and recently in human patients with superficial cell carcinoma of the bladder (treated with H19-DTA). However
this targeted medicine approach could be limited, as not all cancer patients express high levels of H19. Hence, a
double promoter DTA-expressing vector was created, carrying on a single construct two separate genes expressing
the diphtheria toxin A-fragment (DTA), from two different regulatory sequences, selected from the cancer-specific
promoters H19 and IGF2-P4.
Methods: H19 and IGF2-P4 gene expression was tested in samples of Transitional Cell Carcinoma (TCC) of the
bladder by in-situ hybridization (ISH) and by quantitative Real-Time PCR (qRT-PCR). The therapeutic potential of the
double promoter toxin vector H19-DTA-IGF2-P4-DTA was tested in TCC cell lines and in heterotopic and orthotopic
animal models of bladder cancer.
Results: Nearly 100% of TCC patients highly expressed IGF2-P4 and H19, as determined by ISH and by qRT-PCR.
The double promoter vector exhibited superior tumor growth inhibition activity compared to the single promoter
expression vectors, in cell lines and in heterotopic and orthotopic bladder tumors.
Conclusions: Our findings show that bladder tumors may be successfully treated by intravesical instillation of the
double promoter vector H19-DTA-P4-DTA.
Overall, the double promoter vector exhibited enhanced anti-cancer activity relative to single promoter expression
vectors carrying either gene alone.
Introduction
Bladder cancer is the fourth most commonly diagnosed
malignancy in men and the ninth most commonly diag-
nosed malignancy in women, (NCI annual report 2009).
Urinary bladder neoplasm can be grouped into three
different categories: Superficial, invasive and metastatic.
At presentation, 75% of the tumors are superficial, 20%
are invasive and up to 5% have de novo metastasis. The
wall of the bladder is lined with cells called transitional
cells. More than 90% of urothelial cancers in the bladder
are transitional cell carcinomas (TCC). Other important
histologic types include squamous cell carcinoma and
adenocarcinoma [1].
At presentation, tumors are usually limited to the
bladder mucosa (Ta) or submucosa (T1). These tumors
can be removed by transurethral resection (TUR), but
tend to recur in 50-70% of the patients. Measures to
decrease this high recurrence rate include intravesical
chemotherapy and immunotherapy (BCG - Bacillus
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Calmet-Guerin). These treatments decrease the recur-
rence rate, but are associated with side effects and
frequent failures [1].
The target population of this study is patients with
superficial bladder cancer refractory to conventional
therapies. Conventional therapies have focused on mass
cell killing without specific targeting and often cause
damaging and severe side effects to normal tissues. The
development of targeted therapeutic strategies based on
human cancer gene therapy is an attractive approach.
Based on early studies of our group and others, the
transcriptional regulatory sequences of the H19 and IGF2
genes emerged as candidates for cancer targeted therapy.
H19 and IGF2 (the human P3 and P4 promoters) are
onco-fetal genes and are oncogenes [2-4], expressed in
the fetus and in a broad spectrum of tumors, but rarely
in normal adult tissues [5-7]. H19 is a paternally-
imprinted, oncofetal gene that encodes a RNA (with no
protein product) acting as a “riboregulator” [8], which is
expressed at substantial levels in embryonic tissues, in
different human tumor types, and marginally or not
expressed in the corresponding tissues of the adult [6,9].
The 67-aa IGF2 is a member of the insulin like growth
factor family that is involved in cell proliferation and dif-
ferentiation [10]. The human IGF2 gene contains 9 exons
(E1-9) and 8 introns [10,11], and is transcribed from 4
different promoters (P1-P4) producing 4 different tran-
scripts [11-13]. All four transcripts share a common cod-
ing region and a common 3.9 kb 3-UTR, but variable 5-
UTRs [11]. IGF2 is an imprinted gene that is almost
exclusively expressed from the paternal allele [14-16].
The P3 and P4 promoters are the major IGF2 promoters
during embryogenesis and tumor development, while P1
is exclusively active in adult liver tissue and P2 activity is
rarely detected in adult human tissue [10]. Increased
expression of IGF2 as a result of the loss of its imprinting
is frequently seen in a variety of human tumors [16-18].
In addition, abnormal signal transduction and/or promo-
ter activation was reported as a major mechanism for the
IGF2 overexpression in a variety of tumors including
bladder carcinoma, hepatocellular carcinoma, breast can-
cer, ovarian cancer and prostate cancer [19-22]. The
human H19 gene lies within 200 kb downstream of the
paternally expressed IGF2 gene at 11p.15.5. These two
genes are frequently coordinately regulated, both in
terms of their common expression pattern and are reci-
procal imprinting. Enhancers located downstream of H19
stimulate transcription of both genes [23].
We have shown that IGF2 or H19 are significantly
expressed in 50-84% of human bladder carcinomas,
respectively [7,24]. Our group has previously reported
the construction of single promoter vectors expressing
diphtheria toxin A-chain gene, under the control of
IGF2-P4 or H19 regulatory sequences (IGF2-P4-DTA
and H19-DTA). We showed that these constructs were
able to selectively kill tumor cell lines and inhibit tumor
growth in vitro and in vivo in accordance to the tran-
scriptional activity of the above-mentioned regulatory
sequences [7,25]. Moreover, our group used this thera-
peutic approach (using H19-DTA) in a successful treat-
ment of a patient suffering from bladder cancer for a
period of over 6 years [25], a phase I/IIa clinical trial
using this therapeutic approach has been successfully
completed [26] and the FDA has approved the initiation
of following phase IIb clinical trial. However, there are
TCC cells that do not express H19 and as a result, there
are patients that could not match this treatment.
Thus for the first time, in the present study, a double
promoter DTA-expressing vector was created, carrying
on a single construct two separate genes expressing the
diphtheria toxin A-fragment (DTA), from two different
regulatory sequences, H19 and IGF2-P4 (’H19-DTA-P4-
DTA’ vector). This novel approach, create a new family
of plasmids regulated by two regulatory sequences,
which in their natural genome position are both proxi-
mately located and are reciprocally imprinted. This is a
new biology concept, which mimics the unique biology
reciprocity relations phenomenon of IGF2 and H19.
This vector was then used to transfect and to eradicate
tumor cells in culture or to inhibit tumor growth (in vivo),
in heterotopic and orthotopic bladder tumor models.
The activity of the double promoter vector was tested
and compared to the activity of the single promoter
vectors.
The results showed enhanced activity of the double
promoter vector, H19-DTA-P4-DTA, relative to the sin-




The human bladder carcinoma cell line T24P was
obtained from the American Type Culture Collection
(ATCC; Rockville, MD). The human bladder carcinoma
cell line HT-1376 was kindly provided by Prof W.
Schulz, Heinrich-Heine University of Dusseldorf, Ger-
many. Cells were grown to confluency in a humidified
incubator with 5% CO2 in polystyrene culture flasks and
were maintained in DMEM-F12 (1:1) medium contain-
ing 10% fetal calf serum.
RNA Isolation, cDNA Synthesis and PCR
RNA was extracted from cell lines or frozen tissue blocks,
using the RNA STAT-60TM Total RNA/mRNA isolation
reagent, according to the manufacture’s instructions. The
RNA was treated by RNAse-free DNAse I to eliminate
any contaminating DNA. Total cDNA was synthesized
from 2 μg total RNA in 20 μl reaction volume with 10
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ng/μl of the oligo-(dT)15 primer and 10 units/μl M-MLV
Reverse Transcriptase according to the manufacturer
instructions. 2 μl of cDNA samples were taken for the
amplification of the different transcripts using the differ-
ent primers. The amplification conditions were 95°C for
2 min, followed by 30 cycles of 94°C for 30 sec, 59°C for
45 sec and 72°C for 60 sec, and finally 72°C for 5 min.
The PCR reactions were carried out in 25 μl volumes in
the presence of 6 ng/μl of each of the forward and the
reverse primers using 0.05 units/μl of Taq polymerase
according to the kit instructions (Takara). The forward
(5’-CCGGCCTTCCTGAACA) and reverse (5’-TTCCGA
TGGTGTCTTTGATGT) primers designed for the
detection of H19 RNA are spanning exons 2-3 and from
exon 5 respectively, in order to validate that the PCR pro-
duct is of the H19 RNA transcript and not from the
endogenous H19 gene. The primers designed for the
detection of IGF2-P4 RNA were designed to bind at exon
6 (5’-TCCTCCTCCTCCTGCCCCAGCG), for the P4
transcript in the forward direction and the reverse primer
(5’- CAGCAATGCAGCACGAGGCGAAGCC) was
designed to bind the 3’ end of exon 7 and the 5’ end of
exon 8 without the introns in between. The integrity of
the cDNA was assayed by PCR analysis of the ubiquitous,
cell cycle independent, histone variant, H3.3 [7]. The
PCR products were separated by electrophoresis on 2%
gel agarose, and detected by ethidium bromide dye.
Quantitative Real time PCR (qRT-PCR)
Human TCC samples were obtained from patients
undergoing TUR or radical cystectomy at Hadassah
Hospital (Hadassah Hebrew University Medical Center,
Jerusalem, Israel), following permission of the local IRB.
Samples were analyzed using Mx3000p qRT-PCR detec-
tion system and its appropriate software Mx3000p qRT-
PCR Software version 3.20 (Stratagene, La. Jolla, CA).
Samples contained 10 μl of absolute blue qRT-PCR master
mix (ABgene, Epsom, UK), 2 μl of samples, 500 nM of pri-
mers and 100 nM of TaqMan MGB probes (Applied Bio-
systems, Foster City, CA, USA) [27]. Amplification was
done by an initial step of enzyme activation at 95°C, fol-
lowed by 40 cycles of 95°C for 15 sec and 60°C for 1 min.
The amount of FAM fluorescence released from each tube
was measured as a function of the PCR cycle number. To
estimate the sensitivity of the real-time PCR procedure,
three separate plasmid DNA controls were used with 10
fold serial dilutions of known quantities. For H19 analysis,
starting from 0.2 ng (9 × 107 copies) up to 0.2 × 10-7ng (≤
9 copies of plasmid DNA) were used. For IGF2-P4 analy-
sis, starting from 0.2 ng (3 × 107 copies) up to 0.2 × 10-7ng
(≤ 3 copies of plasmid DNA) were used. Simultaneous
amplifications of standard dilution series were then per-
formed. The number of target copies was determined
using the standard curve created in the same run. The
qRT-PCR assays were accepted when a positive signal was
detected in all positive control dilutions and no signal was
detected in the negative sample controls. The threshold
for high expression level was set as >10,000 DNA copies
number (per 0.2 μg c-DNA). These experiments were per-
formed in triplicates.
DIG-labeled Probe Synthesis
A PCR strategy was used to generate template DNA for
synthesis of labeled RNA probes.
Forward primers for the human H19 and IGF2-P4
genes were designed. Each primer contain Sp6 promoter
sequence in its 5’-end. Accordingly, a reverse primer
was also designed with T7 promoter sequence incorpo-
rated in its 5’-end. The PCR products obtained for the
H19 and IGF2-P4 transcript were purified from the gel
by the DNA and Gel Band Purification Kit (Amersham),
and used as templates for the PCR-based incorporation
of T7 and Sp6 RNA polymerase promoter. The PCR
conditions used to generate the T7/Sp6 templates were
the same as described earlier for the synthesis of H19
and IGF2 specific transcripts. The PCR products (con-
taining T7 and Sp6 promoters) were purified from the
gel, sequenced and found to be identical to the relevant
published sequences in the gene bank. 100 to 200 ng
from the purified products were used as templates for
the T7 and Sp6 polymerase (2 units/μl), according to
the manufacturer instructions in the presence of
2 units/μl RNase inhibitor. T7 and Sp6 promoters were
respectively used to drive the synthesis of the antisense
and the control sense Digoxigenin-labeled UTP probes.
The resulting probes were treated by 2 units of RNase
free DNase I, pelleted and resuspended in appropriate
volume of DEPC-treated double distilled water. The
sizes of the synthesized probes were analyzed by run-
ning on 4% denaturing agarose minigel, and their label-
ing efficiency was determined by dot blot analysis.
In situ hybridization (ISH)
The non radioactive ISH washing and treatments were as
described in [7]. Each section was rehydrated by 30 μl of
the hybridization solution containing about 30 ng of DIG
labeled RNA probe at 52°C. The ISH was performed on
successive slides of TCC tissue for H19 and IGF2-P4
transcripts. The intensity of hybridization signal was indi-
cated as (0) for no staining, (+1) for weak, (+2) for mod-
erate and (+3) for strong signals. The distribution of the
hybridization signal was referred to as up to one third of
the cells, + (1), one to two thirds, ++ (2), and more than
two thirds, +++ (3). Therefore the total scoring (intensity
+ quantity) for each sample varied from 0 (no expression)
to 6 (very high expression). Low expression was set as
total scoring of 0 < X < 3 and high expression was set as
total scoring of 3 ≤ X ≤ 6.
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Plasmid construction
The H19-Luc plasmid which contains the luciferase
gene under the control of the human H19 promoter
region from nucleotide -818 to + 14 was prepared as
described [28]. The H19-Luc plasmid was digested with
XbaI and NcoI, and the insert of the luciferase gene
(luc) was replaced by the Diphtheria toxin A chain
(DTA) coding region to yield the H19-DTA construct.
The DTA gene was prepared from the pIBI30-DT-A
plasmid (kindly donated by Dr. Ian Maxwell, University
of Colorado, USA). The human IGF2-P4 promoter from
the Hup4 vector (described in [11]) (a kind gift from
Prof. P.E. Holthuizen, University of Utrecht, The Neth-
erlands) were constructed by GENEART into the pGL3
basic vector (Luc-1) (Promega, Madison, MI), which
lacks any eukaryotic promoter and enhancer sequences
and carries the Kanamycine resistance gene (insert 812
bp), using BstEII and Hind III restriction sites, resulting
in the expression vector P4-Luc. The DTA containing
vector P4-DTA was designed by replacing the luciferase
gene in P4-Luc with the DTA gene between the XbaI
and NcoI restriction sites. Each of the cloned promoters
and the DTA gene were sequenced and compared to
the published sequences of the gene bank. We con-
structed double promoter expression plasmids, carrying
on a single construct two separate genes expressing the
diphtheria toxin, from two different regulatory
sequences, as follows: H19 + IGF2-P4 promoters (here-
inafter “H19-DTA-P4-DTA"; depicted in Figure 1).
A double promoter control constructs was created,
using the same strategy, expressing the luciferase repor-
ter gene (’H19-Luc-P4-Luc’). The double promoter
expression plasmids were cloned by GENEART™,
(Germany)
Transfection
Cationic polymer (jetPEI) transient transfection
The in vitro jetPEI™transfection reagent compact the
DNA into positively charged particles capable of inter-
acting with anionic proteoglycans at the cell surface and
Figure 1 A schematic illustration depicting the construction of the double promoter H19-DTA-P4-DTA expression vector: The coding
sequence of each DTA is under the transcriptional control of both H19 and IGF2-P4 promoter sequences, respectively, Kana (R) - kanamycine
resistance gene.
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entering cells by endocytosis. The transfection proce-
dure was done as recommended by the manufacturer
(Polyplus-transfection, France). A total of 0.1 × 106
cells/well were grown overnight in a twelve-well Nunc
multidish (75 mm). For each well, 2 μg DNA and 4 μl
of the jetPEI (N/P = 5) were diluted separately with
50 μl of 150 mM NaCl each, and vortex-mixed gently.
The jetPEI solution was added at once to the DNA solu-
tion, the mixture was vortex-mixed for 10 seconds and
the mixture was incubated for 15 minuets at room tem-
perature. The 100 μl jetPEI/DNA mixture was then
applied drop-wise onto the serum containing medium of
each well. The transfection experiment was stopped
after 48 hours.
Luciferase activity
The cells were harvested and the luciferase activity was
determined using the luciferase Assay System kit (Pro-
mega). The light output was measured using a Lumac
Biocounter apparatus. The total protein content of the
lysates was determined by the Bio-Rad protein assay
reagent and the results were normalized to the total
protein and expressed as Light units/μg protein.
LucSV40 (Luc-4) was used as a positive control for the
efficiency of transfection as it contains the SV40 promo-
ter and enhancer, while Luc-1 that lacks any regulatory
sequences was used as a negative control to determine
the basal nonspecific luciferase expression, which was
found to be negligible in all of the cell lines. All experi-
ments were done in triplicates and the results expressed
as mean and standard error.
In vitro targeted therapy
The cells were cotransfected with 2 μg of the LucSV40
control vector and with the indicated amounts of the
DTA expressing vector (H19-DTA, P4-DTA or the
DTA double promoter expressing vector H19-DTA-P4-
DTA). The same cells were additionally transfected with
2 μg LucSV40 alone in the same experiment. The H19-
DTA, P4-DTA and H19-DTA-P4-DTA cytotoxic activity
was determined by calculating the % of decrease in the
cotransfected LucSV40 activity compared to that of
LucSV40 transfected alone in the same cell type. The
total protein content of the lysates was determined by
the Bio-Rad protein assay reagent and the results were
normalized to the total protein and expressed as Light
units/μg protein. Therefore the reduction in luciferase
activity, reflect the inhibition of protein synthesis activity
by the DTA.
In vivo targeted therapy animal models
All surgical procedures and the care given to the ani-
mals were approved by the local committee for animal
welfare. Animals were kept in the Hebrew University’s
animal facility with water and food ad librum (all
experimental research on animals follow internationally
recognized guidelines). The histopathological examina-
tions of the different tumors were performed in consul-
tation with a trained pathologist.
Heterotopic nude mice model
Confluent T24P and HT-1376 human bladder carci-
noma cells were trypsinized to a single cell suspension
and resuspended in PBS. 2 × 106 T24P cells or HT-1376
cells (in 150 μl volume) were subcutaneously injected
into the back of female CD1 nude mice, 6-8 weeks old.
10 days after cell inoculation the developing tumors
were measured in two dimensions and randomized to
different treatments. Animals were separated to different
groups of the same size (n = 6). The ability to inhibit
tumor growth by the single promoter DTA expression
vectors (P4-DTA, H19-DTA) and by the double promo-
ter DTA expression vector (H19-DTA-P4-DTA) was
tested. Intratumoral injections of 25 μg of either DTA
expressing constructs (treatment groups) or Luc expres-
sing constructs (control groups) were given 10, 12 and
14 days after cells inoculation. In vivo Jet-PEI a 22 kDa
linear form of polyethylenimine (PEI) was used as a
transfection enhancer reagent. PEI/DNA complexes with
a ratio of PEI nitrogen to DNA phosphate of 6 were
prepared in a solution of 5% w/v glucose according to
the manufacture’s instructions. Tumor dimensions were
measured, and the tumor volume was calculated accord-
ing to the formula width2 × length × 0.5. The animals
were sacrificed 3 days after the last treatment, the
tumors were excised and their ex-vivo weight and
volume were measured. Samples of the tumors were
fixed in 4% buffered formaldehyde and processed for
histological examination for evidence of necrosis and
persistent tumor. Computerized measurements of tumor
surface area and of the necrotic surface area were made
using the Image Pro Plus software (Media cybernetics,
Silver Springs, USA).
Orthotopic bladder cancer model
Female CD1 nude mice, 6-8 weeks old were used to
develop orthotopic superficial bladder tumors. Mice
were anesthetized with intra-peritoneal injection of keta-
mine (85 mg/kg) and xylazine (3 mg/kg). The bladder
was catheterized with a 24 gauge catheter, than drained
and its mucosa was mildly disrupted with 0.1 ml HCl
0.1N for 15-sec. (The bladder is rather resistant to
implantation of cells, and therefore it is necessary to
create abrasions in the bladder mucosa of the anesthe-
tized rodent either by acid, in order to increase “tumor
take” [29]). The acid was immediately neutralized with
0.1 ml NaOH 0.1N, and the bladder was washed three
times with 0.1 ml PBS. Subsequently, a 0.1 ml suspen-
sion of PBS containing 10 × 106 T24P human bladder
carcinoma cells was instilled into the bladder. The ure-
thra was ligated with 6/0 silk suture to assure that cells
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were retained in the bladder. After 2 hours the sutures
were removed and the bladders were evacuated by spon-
taneous voiding. Four healthy mice were left without
T24P cells instillation. Seven days after cell instillation,
the animals were anesthetized and the bladders were
catheterized the same way. The bladders were washed
three times with 0.1 ml of PBS. Animals were separated
to different groups of the same size (n = 6). Mice of the
DTA treatment groups received 20 μg of the toxin vec-
tor H19-DTA-P4-DTA. The control group received 20
μg of the reporter vector H19-Luc-P4-Luc. A group of 4
mice were kept with no treatment. The same treatments
were repeated after 3 days. The in vivo-jetPEI™ was used
as a transfection enhancer agent. For preparation of the
solution, 2.4 μl of the jetPEI (N/P ratio = 6) in 50 μl
glucose 5% (w/v) were mixed with 20 μg of treatment
plasmids respectively, in 50 μl of 5% glucose solution.
The resulting mixture was vortex-mixed and left for 10-
15 minutes at room temperature and subsequently
instilled into the mice bladder transurethrally using the
catheter as described above. The animals were sacrificed
4 days after the last plasmid instillation, their bladders
were removed and the serosal surface and the adjacent
sex glands were dissected carefully. Samples of the
tumors were fixed in 4% buffered formaldehyde and
processed for histological examination for evidence of
necrosis and persistent tumor. Computerized measure-
ments of tumor surface area and of the necrotic surface
area were made using Image Pro Plus software (Media
cybernetics, Silver Springs, USA). Other samples were
frozen by liquid nitrogen and stored at -80°C to be ana-
lyzed by RT-PCR for evidence of IGF2, H19, luciferase
and DTA mRNA expression.
Results
Expression of IGF2-P4 and H19 transcripts in human
bladder carcinoma tissues determined by ISH or by RT-
PCR
The human IGF2-P4 and H19 regulatory sequences are
highly active in a variety of human cancers. In this study
we present an approach for targeted therapy of bladder
carcinoma by driving the DTA expression under the
control of IGF2-P4 and H19 regulatory sequences. To
evaluate the possible use of IGF2-P4 and H19 regulatory
sequences for targeted therapy of bladder cancer, we
determined the expression of IGF2-P4 and H19 tran-
scripts by RT-PCR, qRT-PCR and ISH. Human TCC
samples were obtained from patients undergoing TUR
or radical cystectomy at Hadassah Hospital, following
permission of the local IRB.
The samples were first tested for H19 and IGF2-P4
overall expression by RT-PCR or by ISH (Table 1). 38
out of 39 TCC samples examined by RT-PCR showed
positive IGF2-P4 transcripts expression and 37 out of 39
TCC samples showed positive H19 expression. Accord-
ingly, 24 out of the 28 TCC samples examined by ISH
showed positive IGF2 expression from IGF2-P4 (Figure
2A), and 27 out of the 28 TCC samples showed positive
H19 expression (Figure 2B) (Table 1). Taken together
the PCR and ISH results show that 62 out of 67 (92.5%)
and 64 out of 67 (95.5%) positively expressed varying
levels of IGF2-P4 and H19, respectively.
Comparison of the expression levels of IGF2-P4 and H19
transcripts in human TCC samples detected by ISH and
by qRT-PCR
qRT-PCR and ISH techniques were applied to deter-
mine and quantity the level of H19 and IGF2-P4 in
human TCC samples.
Human TCC samples (n = 29) were examined by
qRT-PCR and the expression level of H19 and IGF2-P4
specific transcripts was determined for each sample by
the total number of DNA copies (per 0.2 μg c-DNA).
Table 2 demonstrates that high levels of IGF2-P4 and
H19 transcripts were found in 83% (24/29) and in 90%
(26/29) of the tumor samples, respectively. However the
total combined expression of both IGF2-P4 and H19
transcripts, were detected at high expression levels in
100% (29/29) of the tumor samples.
Additional human TCC samples (n = 28) were exam-
ined by ISH and the expression levels of IGF2-P4 and
H19 transcripts were determined by the intensity of the
hybridization signal and by the quantity of the stained
cells. Table 3 shows that out of 28 TCC samples, high
expression levels of H19 and IGF2-P4 were found in
75% (21/28) and 50% (14/28) of the TCC samples,
respectively. However when the overall combined
expression analysis of the intensity and quantity of both
transcripts H19 + IGF2-P4 was determined, then 100%
(28/28) of the samples showed positive expression and
26 out of 28 TCC samples (96%) showed high expres-
sion levels.
Expressing DTA from two different regulatory sequences,
using a ‘double promoter strategy’
As described, high levels of H19 and IGF2-P4 tran-
scripts were detected in TCC samples. Furthermore,
enhanced expression was clearly exhibited for a com-
bined expression of both transcripts (H19 + IGF2-P4).
Table 1 The H19 and IGF2-P4 overall expression in TCC
tissue samples determined by RT-PCR (n = 39) and by in
situ hybridization (ISH) (n = 28)
RT-PCR ISH Total
IGF2-P4 38/39 24/28 62/67
H19 37/39 27/28 64/67
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Therefore, we decided to further investigate the com-
bination use of H19 and IGF2-P4 regulatory sequences
for driving toxin gene expression. A double promoter
expression vector was created, carrying on a single con-
struct two separate genes expressing the diphtheria
toxin A (DTA), from two different regulatory sequences,
H19 and IGF2-P4 promoters ("H19-DTA-P4-DTA";
depicted in Figure 1).
In vitro DTA expression by a single construct containing
DTA genes separately expressed from H19 and IGF2-P4
regulatory sequences
The activity of the double promoter construct H19-DTA-
P4-DTA was first tested in vitro by determining its ability
to lyse two different human bladder carcinoma cell lines,
relative to the single promoter constructs. Anti-tumor
therapeutic activity was determined by measuring the inhi-
bition of luciferase activity following co-transfection with
LucSV40. T24P and HT-1376 TCC cells were co-trans-
fected with the indicated vectors (H19-DTA, P4-DTA, or
H19-DTA-P4-DTA) in a dose-response manner at the
indicated concentrations (Figure 3) and with 2 μg of
LucSV40. Luciferase activity as an indicator of survival of
the transfected cells was determined and compared to that
of cells transfected with LucSV40 alone. H19-DTA or P4-
DTA was able to drive the expression of the DTA gene
and thus reduce luciferase activity in a dose-response
manner. H19-DTA-P4-DTA, however, exhibited far
enhanced efficiency in lysing the cancer cell lines, relative
to each of the single promoter constructs, in T24P cells
(Figure 3A-B) and in HT-1376 cells (Figure 3C-D). The
double promoter expressing vector H19-DTA-P4-DTA
was able to reduce the LucSV40 activity to more than 70%
at concentrations as low as (0.005 μg/well) in T24P (Figure
3B) and HT-1376 (Figure 3D) cells, respectively. Less sig-
nificant inhibition was obtained by H19-DTA or P4-DTA
at the same concentrations (0.005 μg/well) in T24P
(Figure 3B) and HT-1376 (Figure 3D) cells.
In vivo tumor growth inhibition by the double promoter
vector in bladder cancer animal models
We used the double promoter construct, H19-DTA-P4-
DTA assessing its tumor growth inhibition activity, by
DTA expression in vivo using heterotopic and orthoto-
pic animal models for bladder cancer.
Expression of IGF2-P4 and H19 transcripts in heterotopic
subcutaneous tumors
In order to develop a model for heterotopic bladder
tumors, T24P or HT-1376 human bladder cancer cells
were subcutaneously injected into the dorsa of 6-7
weeks old CD-1 (nude) female mice. Tumors were
developed 10 days after cell injection, dissected and
total RNA was extracted from the tumors. The expres-
sion of IGF2-P4 and H19 RNA was determined by RT-
PCR analysis. High expression of IGF2-P4 and H19
RNA was found in the heterotopic tumors induced by
T24P cells (Figure 4A lanes 1-2) or by HT-1376 cells
(Figure 4B lanes 1-2). Moreover there was no H19 and
IGF2 expression in normal control mice (lane 3). Inter-
estingly, the expression of H19 and IGF2-P4 RNA in the
heterotopic tumors was higher compared to the in vitro
Figure 2 ISH detection of the expression of IGF2-P4 and H19 transcripts in human TCC tissue samples: IGF2-P4 (A) and H19 (B) specific
transcripts, detected by ISH. The positive stained cells are marked by black arrows (Magnification are ×20).
Table 2 The expression levels of H19 and IGF2-P4
transcripts in human TCC samples (n = 29), determined
by qRT-PCR.
H19 IGF2-P4 H19 + IGF2-P4
Low expression 3/29 5/29 0/29
High expression 26/29 24/29 29/29
* (High expression: >10,000 DNA copy numbers (per 0.2 μg c-DNA), as
described in the “Material and Methods”).
Table 3 The endogenous H19 and IGF2-P4 expression
levels in TCC tissue samples determined by ISH.
H19 IGF2-P4 H19 + IGF2-P4
Low expression 6/28 10/28 2/28
High expression 21/28 14/28 26/28
The table shows the level of IGF2-P4 and H19 transcripts, defined as ‘Low’ or
‘High’ expression. A semi quantitative scoring system was established to
define the levels of H19 expression after ISH (see “Material and Methods”).
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expression of T24P cells (lane A4) or HT-1376 cells
(lane B4) used for inoculation.
Tumor growth inhibition by the double promoter vector
in heterotopic bladder carcinoma model
The tumor growth inhibition activity of H19-DTA-P4-
DTA was tested in heterotopic bladder tumors, induced
by T24P cells. T24P cells were subcutaneously injected
into the back of 6-7 weeks old CD-1 female mice in
order to develop a model for heterotopic bladder cancer.
10 days after subcutaneous cell inoculation, the mice
developed measurable heterotopic tumors for testing.
The therapeutic potency of the vectors was tested by
direct intratumoral injection of 25 μg of the DTA
expression vectors (H19-DTA, P4-DTA, or H19-DTA-
P4-DTA), or of the control vectors (H19-Luc, P4-Luc,
or H19-Luc-P4-Luc) into each heterotopic bladder
tumor. Tumors sizes were determined and the in vivo
fold increase of the tumor size was calculated prior to
each treatment and before sacrifice. Three injections of
Figure 3 In vitro enhanced protein synthesis inhibition activity of H19-DTA-P4-DTA in human bladder carcinoma cell lines: Tumor
growth inhibition activity of the H19-DTA, P4-DTA and H19-DTA-P4-DTA vectors in T24P (A-B) and HT-1376 (C-D) cells was measured as a
reduction of LucSV40 activity. Cells were cotransfected with 2 μg of LucSV40 and the indicated concentrations of the DTA expressing vectors, or
with LucSV40 alone. Transfection experiments were stopped after 48 hours and luciferase activity was assessed. The decrease in LucSV40 activity
was determined by comparison to the same cell type transfected with LucSV40 alone as a measure for cytotoxicity. The diverse effect of each
vector at the lowest plasmid transfected concentration is indicated (B, D).
Figure 4 The expression of H19 and IGF2-P4 in heterotopic subcutaneous tumors determined by RT-PCR: The expression of H19 and
IGF2-P4 transcripts in heterotopic subcutaneous tumors after injection of T24P (A) or HT-1376 cells (B) was determined by RT-PCR. “M": 100-bp
molecular weight marker, lanes 1-2: heterotopic subcutaneous tumors from different mice induced by injection of T24P (A) or HT-1376(B) cells,
lane 3: subcutaneous tissue of normal mouse, lanes 4: T24P (A) or HT-1376(B) cell lines, “C": negative control for PCR. The sizes of the PCR
products are 300 bp for human H19, 119 bp for IGF2-P4 and 213 bp for Histone 3.3 internal control, respectively.
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H19-DTA or P4-DTA (Figure 5) at two-day intervals
were able to inhibit tumor development by 49% (P =
0.001) and 55.5% (P = 0.005), respectively compared to
H19-Luc and P4-Luc treatments. However, three injec-
tions of the double promoter plasmid H19-DTA-P4-
DTA at two-day intervals inhibited tumor development
by 70% (P < 0.001) compared to H19-Luc-P4-Luc treat-
ment (Figure 5). The double promoter construct thus
exhibited enhanced ability to inhibit tumor development
in vivo, compared to each of the single-promoter con-
structs (H19-DTA, or P4-DTA).
To confirm the difference between the H19-DTA-P4-
DTA and H19-Luc-P4-Luc groups, tumors were excised
and their ex vivo volume and weight were determined as
well. Mice treated with H19-DTA-P4-DTA exhibited a
61% (P < 0.001) reduction of the ex-vivo tumor volume
(Figure 6A) and a 54% (P = 0.002) reduction of the ex-
vivo tumor weight (Figure 6B) compared to H19-Luc-
P4-Luc treated mice. The consistency of the results, in
measurements of the ex-vivo tumors as well, eliminates
any unrelated difference of the measurements (such as
subcutaneous inflammation swelling due the necrosis
reaction, etc.).
In vivo tumor growth inhibition of orthotopic bladder
tumors by the double promoter vector
Transurethral implantation of human bladder cancer
cells into the mouse bladder (orthotopic model)
provides a more relevant tool for the investigation of
the biology and therapy of bladder cancer than subcuta-
neous implantation of bladder cancer cells (heterotopic
model). Therefore, a mouse model was developed by
intravesical instillation of T24P human bladder carci-
noma cells onto the wall of the mouse bladder in vivo.
This model was then used for testing the tumor growth
inhibition activity of the double promoter H19-DTA-P4-
DTA vector.
Treatment of the orthotopic tumors
Considerably large tumors were obtained 14 days after
the T24P cells inoculation. As shown in Figure 7A high
expression of both H19 and IGF2-P4 was determined by
RT-PCR, in orthotopic bladder tumors, sacrificed 14 days
after cells inoculation. By this time the tumors already
started to invade the lamina propria as well as the super-
ficial and deep muscle (Figure 7B). These tumors would
not therefore be suitable to start the treatment by the
DTA therapeutic constructs because it does not resemble
the stage at which most of the cases in human (more
than 75%) consult the physician. Therefore, the treatment
was started 7 days after cells inoculation, which was
enough to develop smaller and less invasive orthotopic
tumors than after 14 days. The treatment group (n = 6)
was intravesically treated with 20 μg of H19-DTA-P4-
DTA and the control group (n = 6) received 20 μg of
H19-Luc-P4-Luc. Three days later the same treatments
Figure 5 In vivo inhibition of heterotopic tumors in response to H19-DTA-P4-DTA treatments. Inhibition of tumor growth in response to
H19-DTA, P4-DTA, or H19-DTA-P4-DTA treatments is shown. The tumor sizes of tumors treated with the DTA expressing vector, or with control
luciferase expressing vectors were determined prior to each treatment and before sacrifice. The fold increase in tumor volume was calculated
relative to the initial volume at the day of the first treatment.
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Figure 6 Heterotopic tumors treated by H19-DTA-P4-DTA. Heterotopic bladder tumors treated with H19-DTA-P4-DTA vector (black) or with
H19-Luc-P4-Luc control vector (white) were excised and the ex-vivo tumors volume were measured (A) and weighted (B). C-D: Necrosis of
heterotopic tumors treated with H19-DTA-P4-DTA: Hematoxylin Eosin (HE) staining (×10) of representative sections of tumors treated with H19-
Luc-P4-Luc (C), or with H19-DTA-P4-DTA (D). The necrotic areas are indicated by arrows (D). Inserts are macroscopic photographs of the
heterotopic tumors.
Figure 7 Orthotopic bladder tumors kinetics, 14 days after intravesical cells instillation: A). “M": 100-bp molecular weight marker, lanes 1-
3: orthotopic bladder tumors from different mice induced by intravesical instillation of 10 × 106 T24P cells, lane 4: bladder of normal mouse, “c":
negative control for PCR. B). HE staining (×10) of a representative section of orthotopic bladder (14 days after intravesical inoculation of 10 × 106
T24P cells). The tumor area is indicated (by green line). (’U’, urothelium, ‘LP’, lamina propria, ‘M’, muscularis).
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were repeated. Additional four control healthy mice were
intravesically treated with HCL/NaOH at the beginning
of the experiment with no additional following treat-
ments. The animals were sacrificed at the end of the
experiment (4 days after the second treatment), their
bladders were processed for assessment of tumor sizes
and for PCR and histology analyses (see Materials and
Methods).
As can be seen in Figure 8, two treatments of 20 μg of
H19-DTA-P4-DTA in three day intervals were able to
inhibit tumor growth significantly as reflected by mea-
suring the size of the tumors and by bladders weight.
Tumor area of each bladder was macroscopically
determined, using the ImagePro Plus software for mea-
surement and analysis of the tumor area. The average
size of the H19-DTA-P4-DTA treated tumors at the end
of the experiment was 86% smaller (Figure 8A) than
that of the H19-Luc-P4-Luc treated ones (6.37 ± 2.1
mm2 and 44.6 ±8.5 mm2 respectively) (P < 0.001). As
shown in Figure 9B, the group treated with the reporter
vector showed usually more than one large lesion, with
different grades of invasion. In contrast, only small
tumors were detected in the H19-DTA-P4-DTA treated
bladders (Figure 9E).
Inhibition of tumor growth was also reflected in blad-
ders weight (Figure 8B). The mean bladder weight of H19-
DTA-P4-DTA treated mice was 40 ± 9 mg compared to
120 ± 20 mg in the control group. The mean bladder
weight of the healthy mice was 30 ± 3 mg (P < 0.001).
Expression of DTA and Luc RNA in mouse orthotopic
treated bladder tumors
At the end of the experiment, bladders were excised and
total RNA was extracted from each tumor. RNA sam-
ples from the treated tumors were analyzed by RT-PCR
for DTA and for luciferase mRNA expression. Figure
10A (lanes 1-2) shows high luciferase expression after
treatment with the H19-Luc-P4-Luc reporter vector.
The PCR revealed DTA mRNA expression in H19-
DTA-P4-DTA treated tumors (lanes 3-4) but not in the
luciferase treated tumors (lanes 1-2). This indicates that
the tumors were efficiently transfected by the H19-DTA-
P4-DTA vectors and that the human H19 and IGF2-P4
promoters were activated and DTA was produced.
Figure 8 The effect of intravesical treatment with H19-DTA-P4-DTA vector in orthotopic bladder carcinoma: Orthotopic tumors were
induced by intravesical instillation of T24P cells, in nude mice bladders. 7 days later, mice of each group (n = 6) received an intravesical
treatment with 20 μg of H19-DTA-P4-DTA, or H19-Luc-P4-Luc for each mouse. The same treatments were repeated after 3 days, and 4 days later
mice were sacrificed. The bladders of both groups were excised, weighted, and the area of the malignant tissue of each bladder was
determined by ImagePro Plus software. Another 4 healthy mice were used as control. The total tumor area of each bladder was determined and
the mean of the total areas was calculated for each group. The Mean and SD of bladder tumor area (A) and weight (B) are shown.
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Necrosis in H19-DTA-P4-DTA treated bladder, as a
result of the diphtheria toxin activity, is shown in figure
10B.
In vitro enhanced activity of the double promoter H19-
DTA-P4-DTA construct compared to combination of the
single promoter constructs
The presence of an enhanced anti-cancer activity of the
double promoter construct H19-DTA-P4-DTA was
tested in the human bladder cancer cell lines T24P and
HT-1376. T24P and HT-1376 cells were co-transfected
with 2 μg of LucSV40 and either (a) the concentrations
indicated (Figure 11) of single-promoter constructs
H19-DTA + P4-DTA in combination, or (b) the same
amount of H19-DTA-P4-DTA as for one of the single-
promoter constructs. The total amount of DNA co-
transfected in samples receiving both single promoter
constructs was therefore twice than the cells transfected
with H19-DTA-P4-DTA. Luciferase activity was deter-
mined and compared to that of cells transfected with
LucSV40 alone. The double-promoter construct H19-
DTA-P4-DTA exhibited enhanced efficiency in lysing
the cancer cell lines, relative to the combined activity of
both single promoter constructs (H19-DTA + P4-DTA),
in T24P cells (Figure 11A-B). Very similar results were
obtained in HT-1376 cells (Figure 11C-D).
In vivo additive activity of the double promoter construct
compared to combination of the single promoter
constructs
The presence of an additive tumor growth inhibition activ-
ity of the double promoter construct H19-DTA-P4-DTA
was tested in vivo in a nude mice heterotopic bladder can-
cer model (described hereinabove). The therapeutic
potency of the vector was tested by 3 intratumoral injec-
tions, at two-day intervals, of 25 μg of H19-DTA-P4-DTA
or of the control vector (H19-Luc-P4-Luc), into each het-
erotopic bladder tumor. Tumor size was determined and
in vivo fold increase of the tumor size was calculated at
the end of each treatment.
To test whether the in vivo tumor growth inhibition
activity of H19-DTA-P4-DTA was augmented-than-
additive, an additional group of T24P tumor-containing
mice was treated with three injections of 25 μg each of
single-promoter constructs H19-DTA + P4-DTA in
combination. The total amount of DNA co-transfected
administered was therefore twice (50 μg) than the H19-
DTA-P4-DTA group.
As can be seen in Figure 12, tumor development in
mice receiving both H19-DTA and P4-DTA plasmids
was inhibited by 63.4% (P = 0.001) compared to com-
bined H19-Luc + P4-Luc treated mice. However, an
enhanced effect was observed in mice treated with the
double-promoter construct H19-DTA-P4-DTA, wherein
tumor development was inhibited by nearly 70% (P =
0.005) compared to mice treated with the control plas-
mid H19-Luc-P4-Luc. Figure 12 summarizes all T24P
heterotopic bladder cancer model results. H19-DTA-P4-
DTA clearly exhibits enhanced activity compared to
each of the single promoter plasmids alone and also
superior to their combined activity. As can be seen in
Figure 12, mice intratumorally treated with higher dose
as 50 μg of the double-promoter construct H19-DTA-
P4-DTA (same total amount of the combined single
promoter plasmids), showed enhanced inhibition of
more than 80%.
Thus, the H19-DTA-P4-DTA vector exhibits augmen-
ted-than-additive in vivo tumor growth inhibition activ-
ity, compared to the combined activity of both single-
promoter constructs (H19-DTA and P4-DTA).
Discussion
The present work shows the successful use of a double
promoter expressing vector, carrying on a single con-
struct two separate DNA sequences expressing the
diphtheria toxin A-fragment (DTA), from two different
regulatory sequences, selected from the cancer-specific
promoters H19 and IGF2-P4. This construct was used
to transfect and to eradicate tumor cells in culture (in
vitro) or tumors developed in animal models (in vivo) of
bladder carcinoma.
Cancer is a multigene and multi-factorial disease. The
last decade has seen the emergence of numerous multi-
gene expression profiles that aim to outdo traditional
predictive and prognostic factors (reviewed by [30]).
However, targeted therapies such as Herceptin and
Figure 9 Macroscopic and histopathological views of the
orthotopic bladders treated with H19-DTA-P4-DTA: Shown are
macroscopic photographs of the whole orthotopic bladders treated
with H19-Luc-P4-Luc (A), or with H19-DTA-P4-DTA (D). The bladders
of both of the groups were excised, and the area of the malignant
tissue of each bladder is indicated (by grin line) for the H19-Luc-P4-
Luc (B) and H19-DTA-P4-DTA (E). Histopathological microscopic view
(H&E × 10 is shown for H19-Luc-P4-Luc treated bladder (C), or with
H19-DTA-P4-DTA treated bladder (F) and the tumor areas are
indicated (by green line), (’U’, urothelium,’LP’, lamina propria, ‘M’,
muscle).
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Avastin, are targeting one specific protein. Further per-
sonalized and targeted therapies should be considered,
targeting more than one target (protein or a gene).
Accordingly, several chemotherapies nowadays are
administrated as cocktails, in combination with radio-
therapy (reviewed by [31]) and in combination with tar-
geted agents (reviewed by [32]).
Therefore, we applied an innovative approach using
on a single construct more than one specific marker
gene which are differentially expressed in tumor cells,
for targeted cancer therapy.
IGF2 and H19 are reciprocally imprinted and are
highly expressed in a broad spectrum of tumors, but
rarely in normal adult tissues [7,33]. Using a single pro-
moter (e.g. an H19 promoter or an IGF2-P4 promoter)
alone for expression of a cytotoxic gene presents several
unresolved problems. For one, not every tumor cell of a
given type of cancer is positive for expression via the
H19 promoter or the IGF2-P4 promoter sequences.
Thus, such therapy could fail in a sizable proportion
of patients, even without accounting for tumor muta-
genesis. Determination of responsiveness to such con-
structs would involve the costly and difficult step of
genotyping individual tumors.
Tumors are known to exhibit significant genomic
instability and heterogeneity. Thus, even individuals
with an H19-expressing tumor, for example, may
contain some cancer cells that have downregulated or
abrogated H19 expression via mutation. Therefore,
expressing the cytotoxic gene from a single promoter in
such patients may result in temporary and partial tumor
regression that will rapidly be reversed when the cells
containing these mutations survive and rapidly multiply.
Therefore the use of double promoter expressing vec-
tors is highly novel. Tumor cells can express high levels
of H19 and IGF2, or only one of those genes. That way,
majority of the tumor cells could efficiently express the
diphtheria toxin.
This novel approach, create a new family of plasmids
regulated by two regulatory sequences, which in their
natural genome position are both proximately located
and are reciprocally imprinted. This is a novel biology
concept, which mimics the unique biology reciprocity
relations phenomenon of IGF2 and H19.
Once introduced into target tissue, the plasmid vectors
have several advantages over viral vectors (reviewed by
[34,35]): (1) the plasmids have no potential to be infec-
tious; (2) they possess levels of expression per cell that are
Figure 10 Detection of DTA and Luc transcripts in orthotopic bladder tumors: Mice with heterotopic bladder tumors were intravesically
treated twice in 3 days interval, and were sacrificed 4 days after the last treatment. Tumors were excised and frozen immediately and 400 ng
RNA (extracted from the tumors) was used for determination of luciferase and DTA by RT-PCR reaction. A). tumors treated with H19-Luc-P4-Luc
(lanes 1-2), or with H19-DTA-P4-DTA (lanes 3-4). Lane 5: untreated orthotopic bladder tumor, ‘C’: negative control for PCR, ‘M’: 100 bp DNA
ladder. The sizes of the PCR products are 468 bp and 328 bp, for DTA and Luc respectively. The lower panel shows the histone 3.3 internal
control. Necrosis of orthotopic bladder tumor treated with H19-DTA-P4-DTA (H&E × 20) is shown (B) and the necrotic area is indicated (by green
line). (’U’, urothelium, ‘LP’, lamina propria, ‘M’, muscle).
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equivalent to some viral vectors that persist as extra-chro-
mosomal elements; (3) the lack of immunogenicity, thus
allowing for repeated treatments; (4) plasmids transfect
mainly dividing cells, with contrast to most viral vectors
that, except for retroviral vectors, which transfect both
dividing and non dividing cells; and finally (5) the long-
term stability, safety and the lack of need special treat-
ments or storage requirement of the plasmid vectors.
In this study, the therapeutic potential of the vectors
was tested in TCC of the bladder. The bladder has long
been thought to be an ideal target for DNA based ther-
apy because it is easily accessible by catheter and is lar-
gely a self-contained “bag-like” organ. While the
protective glycosaminoglycan (GAG) that is present in
the normal bladder mucosa interferes with the plasmid
transfection [36], it is not present in the bladder tumor,
allowing efficient transfection of principally the tumor
urothelium. In the same way an orthotopic model can
be designed, which the bladder can then be easily
approached by catheter.
In cancer gene therapy, direct DNA injection is cur-
rently a reliable, reproducible, and simple technique
for intratumoral gene transfer [37]. We transferred the
plasmids into cell lines and into the target tissue of the
animal models, as complex with the linear cationic
polyethylenimine (jetPEI) as a transfection reagent.
This method was chosen based on previous studies of
our group showing relatively high levels of transfection
efficiency, in vitro, in vivo and lately in TCC patients
as part of a phase I/IIa bladder cancer clinical trial
[25,27]. JetPEI condenses the DNA into positively
charged particles capable of interacting with anionic
proteoglycans at the cell surface and entering by endo-
cytosis [38].
Subunit A of the diphtheria toxin (DTA), a highly
potent poison, was chosen as an effector molecule. When
only the cDNA coding for the A-fragment is expressed,
the released DT-A toxin from the lysed cells will not be
able to enter neighboring cells in the absence of the DT-
B fragment [39]. This approach not only will insure high
killing activity but will be of great advantage against any
unintended toxicity to non-target normal cells. More-
over, introduction of DTA DNA sequence under the con-
trol of regulatory sequences of genes differentially
Figure 11 Enhanced activity of H19-DTA-P4-DTA in human bladder carcinoma cell lines: The protein synthesis inhibition activity of the
H19-DTA-P4-DTA vector in T24P (A-B) and HT-1376 (C-D) cells was measured as a reduction of LucSV40 activity, and was compared to the
combination activity of H19-DTA + P4-DTA. Cells were cotransfected with 2 μg of LucSV40, and with the indicated concentrations of the DTA
expressing vectors or LucSV40 alone. Transfection experiments were stopped after 48 hours and luciferase activity was assessed. The decrease in
LucSV40 activity was determined by comparison to the same cell type transfected with LucSV40 alone as a measure for cytotoxicity. Enhanced
effect of H19-DTA-P4-DTA vector at the lowest plasmid transfected concentration (0.005 μg compared to 0.005 μg + 0.005 μg of the
combination transfection of both vectors H19-DTA + P4-DTA) is indicated (B, D).
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expressed in tumors but not in adjacent non-tumor cells
will selectively favor the specificity of the treatment.
Over plurality of cancer specific promoters, H19 and
IGF2-P4 regulatory sequences were selected for target-
ing cancer cells. The H19 and IGF2-P4 regulatory
sequences are expected to be good candidates for speci-
fically inducing the expression of DTA in target tumor
cells but not in cells of normal tissue. They are known
to be differentially over-activated in various tumor types
and to show no or minimum activity in the surrounding
normal tissue [40,41]. This is in addition to the known
autocrine/paracrine mode of IGF2 mitogen action in the
development of a wide range of human malignancies.
Accordingly, destruction of the H19 and IGF2 expres-
sing tumor cells not only will eliminate part of the
tumor but will also diminish the supply of mitogenic
IGF2 to neighboring tumor and non-tumor cells and
may lead to arrest of tumor growth and prevent follow-
ing metastases process [42,43].
Based on previous results of our group demonstrating
efficient treatment of TCC using either H19-DTA or
IGF2-P4-DTA vector [25], it appeared that TCC tumors
could be efficiently treated by each of these vectors.
Based on this assumption we hypothesized that by using
double promoter expression vector, which the expres-
sion of DTA is controlled by more than one regulatory
sequence, a higher therapeutic potential is expected, if
the tumor shows high specific expression from more
than one of the above mentioned regulatory sequences
(H19 or IGF2-P4).
In order to determine the applicability of this assump-
tion, the first stage was to explore the expression level
of each of the mentioned regulatory sequences and then
compare it to the combined expression level (from the
two regulatory sequences).
First, the overall expression of H19 and IGF2-P4 was
analyzed by ISH and RT-PCR in 67 human TCC
samples.
Taken together the PCR and ISH analyses results
show (Table 1) that 62 out of 67 (92.5%) and 64 out of
67 (95.5%) positively expressed varying levels of IGF2-P4
and of H19, respectively.
Next, the quantitative expression was further analyzed
by ISH and by qRT-PCR.
Out of 29 TCC samples detected by qRT-PCR,
(Table 2), high levels of IGF2-P4 and H19 transcripts
were found in 83% (24/29) and in 90% (26/29) of the
tumor samples, respectively. Moreover, the total com-
bined expression of both IGF2-P4 and H19 transcripts
was detected at high expression levels in 100% (29/29)
of the tumor samples.
Out of 28 TCC samples detected by ISH (Table 3),
high levels of IGF2-P4 and H19 transcripts were found
in 50% (14/28) and 75% (21/28) of the TCC samples
Figure 12 Augmented-than-additive activity of H19-DTA-P4-DTA in heterotopic bladder tumors, induced by T24P cells. The inhibition
of heterotopic bladder tumor growth, induced by T24P cells is indicated by the fold increase of each DTA mice treated group compared to the
control Luc treated mice. Shown are tumors treated with: 25 μg of H19-DTA, 25 μg of P4-DTA, 25 μg of H19-DTA + 25 μg of P4-DTA 25 μg of
H19-DTA-P4-DTA and 50 μg of H19-DTA-P4-DTA.
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respectively. When the overall combined expression ana-
lysis of the intensity and quantity of both transcripts
H19 + IGF2-P4 was determined, then 100% (28/28) of
the samples showed positive expression and 26 out of
28 TCC samples (96%) showed high expression.
Thus, both ISH and qRT-PCR detections confirmed
that by analyzing the combined expression from two
promoters, 100% of the samples show positive expres-
sion and nearly 100% show high expression.
These results clearly support the rationale of our
hypothesis, which DTA could be extensively expressed
from more than one specific regulatory sequence.
Therefore, we further investigated the combination use
of H19 and IGF2 regulatory sequences for driving toxin
gene expression in therapeutic vectors for bladder can-
cer treatment.
The double promoter construct H19-DTA-P4-DTA
exhibited far superior efficiency in vitro (Figure 3), in
lysing human bladder carcinoma cell lines, relative to
each of the single promoter constructs carrying either
DTA DNA sequence alone (H19-DTA or P4-DTA).
Therefore we further evaluated the therapeutic poten-
tial of the double promoter toxin vector in heterotopic
and orthotopic mouse models.
1. Heterotopic bladder cancer model was used to eval-
uate tumor growth inhibition of the double promoter
vectors compared to that of the single promoter vectors.
The advantages of this model are its rapidity, reproduci-
bility, accessibility and visibility of tumors. When using
immuno-deficient animal like the nude type mice,
human cell lines can be employed and better simulation
of human tumor is obtained. H19-DTA-P4-DTA exhib-
ited superior ability to inhibit heterotopic tumor devel-
opment by 70% (P < 0.001) compared to H19-DTA or
P4-DTA activity (Figure 5).
Additional Ex-vivo measurements of tumors weight
and volume, re-confirmed the difference between the
H19-DTA-P4-DTA and control groups. The consistency
of the results, by measuring of the ex-vivo tumors as
well (Figure 6), eliminates any unrelated difference of
the measurements (such as subcutaneous inflammation
swelling due to necrosis reaction, etc.).
2. The disadvantage of the heterotopic model is the
weak correlation in histology and clinical course
between this model and the clinical disease. Therefore
by inducing orthotopic TCC tumors in mice bladders,
tumors resemble human bladder tumors by their histol-
ogy, by the clinical course of TCC (local tumor growth,
invasion, and metastatic activity), and by the ability to
treat bladder tumors intravesically, the same way human
bladders are clinically treated. Therefore we evaluated
the feasibility of intravesical therapy of H19-DTA-P4-
DTA, in nude mice orthotopic bladder cancer model.
The average size of the H19-DTA-P4-DTA treated
tumors was 86% smaller than that of the H19-Luc-P4-
Luc treated ones (P < 0.001) (Figure 8A) and there was
also significant difference in mean bladders weight (P <
0.001) (Figure 8B). Only small tumors were detected in
the H19-DTA-P4-DTA treated bladders (Figure 9), com-
pared to large lesions and with different grades of inva-
sion in the group treated with the reporter vector.
However the tumors were not completely destructed
and it should be stressed that in patients with bladder
cancer, the tumors are first surgically completely
resected and the purpose of the following intravesical
treatment is therefore to treat any possible remaining
tumor cells and to prevent tumor recurrence.
The inhibition of tumor progression resulted exclu-
sively from the toxic effect of the diphtheria toxin. This
was confirmed by RT-PCR determining mRNA expres-
sion of DTA only in heterotopic tumors treated with
DTA expressing vector (Figure 10A), and by perfor-
mance of cellular necrosis in H19-DTA-P4-DTA treated
tumors compared to the H19-Luc-P4-Luc treated and
non-treated ones (Figure 10B).
In addition, all of the tested orthotopic tumor samples
showed high expression of H19 and IGF2-P4 transcripts
(Figure 7), thus it strongly prove the assumption that
the orthotopic tumor cells activate the H19 and IGF2-
P4 promoters and therefore drive the expression of
DTA within the cells and in consequence triggering
their necrosis.
Finally, we dealt with the question whether transfec-
tion of both single promoter vectors (expressing the
diphtheria toxin) in combination, may exhibit better effi-
cacy than transfection of the double promoter construct.
The use of double promoter vectors was previously
described [44] as a convenient tool for evaluation of the
activity of a gene of interest by monitoring a reporter
gene activity simultaneously expressed on the same con-
struct. However an additive activity of the double pro-
moter vector versus combination of two single promoter
vectors was never demonstrated. Therefore the presence
of an additive anti-cancer effect of the double promoter
constructs H19-DTA-P4-DTA was tested in vitro, in
human TCC cells and in vivo, in heterotopic bladder
cancer mice.
In vitro enhanced activity of the double promoter vec-
tor H19-DTA-P4-DTA (Figure 11) was exhibited in
T24P bladder cancer cells. A superior activity of the
double promoter vector in lysing the cancer cell lines
was exhibited, relative to the combined activity of both
single promoter constructs (H19-DTA + IGF2-P4-
DTA), in a dose response manner. It should be stressed
that the total amount of DNA co-transfected in cells
receiving both single promoter constructs was therefore
twice than the cells transfected with the double promo-
ter constructs.
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Thus, H19-driven and IGF2-P4-driven DTA-encoding
sequences presented on a single expression vector (H19-
DTA-P4-DTA), exhibited enhanced protein synthesis
inhibition activity, relative to expression vectors carrying
either DTA sequence alone when tested against bladder
cancer cells.
Augmented-than-additive activity of the double pro-
moter vectors H19-DTA-P4-DTA (Figure 12) was
further exhibited in vivo, in heterotopic tumors induced
by T24P bladder cancer cell lines. Heterotopic tumors
treated with combination of total amount of 50 μg of
both single promoter H19-DTA and -P4-DTA con-
structs, were inhibited by 63% (P = 0.001) compared to
combined H19-Luc + P4-Luc, control treated mice
(Figure 12). However, an enhanced effect was observed
in mice treated with only 25 μg of the double-promoter
construct H19-DTA-P4-DTA, wherein tumor develop-
ment was inhibited by 70% (P = 0.005) compared to the
mice treated with the control plasmid H19-Luc-P4-Luc.
Tumors treated with higher dose as 50 μg of the dou-
ble-promoter construct H19-DTA-P4-DTA (same total
amount of the combined single promoter plasmids),
showed enhanced inhibition of at least 80% (Figure 12).
Thus, the H19-DTA-P4-DTA vector exhibited augmen-
ted-than-additive in vivo anti-cancer activity, compared
to the combined activity of both single-promoter con-
structs (H19-DTA and P4-DTA.
Conclusions
In this study double promoter expression vector were
used, expressing DTA from two different regulatory
sequences, H19 and IGF2-P4.
Several reasons support this strategy. First, IGF2-P4
and H19 are reciprocally imprinted and are exclusively
expressed at high levels in cancer cells and not in nor-
mal cells. We demonstrated that combined expression
from the two separate regulatory sequences, showed
complementary expression profile, in which nearly 100%
of tumor samples expressed high levels from at least
one of the regulatory sequences. By that the DTA could
be better expressed in larger number of cancer cells and
therefore enhance the tumor inhibition activity.
Second, H19 and IGF2 play major role in tumor devel-
opment. By selective killing of cancer cells, which express
H19 and IGF2, the treated tumor cells as well as the
neighboring tumor cells (as IGF2 mediate its effect in
autocrine/paracrine manner) are at least partly deprived
of their IGF2 supply. By that the targeted destruction of
cancer cells expressing IGF2 or H19, companied by
enhanced bystander effect, may lead to arrest of tumor
growth and prevent following metastases process.
Overall, the double promoter vector, H19-DTA-P4-
DTA, exhibited augmented-than-additive anti-cancer
activity relative to single promoter expression vectors
carrying either DTA sequence alone, when tested
against bladder tumor cells.
As H19 and IGF2-P4 are expressed at very high levels
in a broad spectrum of different cancers, therefore we
propose a double promoter expression approach for tar-
geted cancer therapy. According to this approach
patients will be treated with specific double promoter
expression toxin vector which are under the control of
the IGF2-P4 and H19 regulatory sequences, differentially
expressed in those cancers.
Moreover, our proposed treatment may be applied in
combination with other cancer therapy methods, such
as chemotherapy and radiology. This approach should
be tested in appropriate animal models.
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